S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:ADXN

Addex Therapeutics (ADXN) Stock Price, News & Analysis

$12.80
+0.45 (+3.64%)
(As of 03/28/2024 ET)
Today's Range
$12.25
$12.92
50-Day Range
$7.05
$13.10
52-Week Range
$5.00
$23.40
Volume
4,843 shs
Average Volume
9,755 shs
Market Capitalization
$12.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Addex Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Addex Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($17.20) to ($11.80) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.23 out of 5 stars

Medical Sector

917th out of 938 stocks

Pharmaceutical Preparations Industry

412th out of 422 stocks

ADXN stock logo

About Addex Therapeutics Stock (NASDAQ:ADXN)

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

ADXN Stock Price History

ADXN Stock News Headlines

Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Addex to Present at Biotech Showcase™ 2024
Addex Therapeutics Ltd
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Addex Creates Treasury Shares
Addex Therapeutics Posts Narrower Loss In Q3 - Quick Facts
Addex Convenes Extraordinary General Meeting
Addex Therapeutics: Addex Completes ADS Ratio Change
Addex Completes ADS Ratio Change
Addex To Implement ADS Ratio Change
H.C. Wainwright Reaffirms Their Hold Rating on Addex Therapeutics (ADXN)
See More Headlines
Receive ADXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADXN
Employees
24
Year Founded
N/A

Profitability

Net Income
$-21,800,000.00
Net Margins
-550.78%
Pretax Margin
-549.49%

Debt

Sales & Book Value

Annual Sales
$1.51 million
Book Value
$8.01 per share

Miscellaneous

Free Float
843,000
Market Cap
$12.67 million
Optionable
Not Optionable
Beta
1.62
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Timothy Mark Dyer (Age 56)
    Co-Founder, CEO & Director
  • Dr. Roger G. Mills M.D. (Age 67)
    Chief Medical Officer & Director
  • Mr. Lénaic Teyssédou (Age 38)
    Head of Finance
  • Dr. Jean-Philippe Rocher Ph.D. (Age 65)
    Head of Discovery - Chemistry
  • Dr. Robert Lutjens (Age 56)
    Head of Discovery - Biology
  • Dr. Mikhail Kalinichev Ph.D. (Age 57)
    Head of Translational Science

ADXN Stock Analysis - Frequently Asked Questions

Should I buy or sell Addex Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Addex Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADXN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXN, but not buy additional shares or sell existing shares.
View ADXN analyst ratings
or view top-rated stocks.

How have ADXN shares performed in 2024?

Addex Therapeutics' stock was trading at $6.05 at the beginning of 2024. Since then, ADXN shares have increased by 111.6% and is now trading at $12.80.
View the best growth stocks for 2024 here
.

Are investors shorting Addex Therapeutics?

Addex Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 11,900 shares, an increase of 41.7% from the February 29th total of 8,400 shares. Based on an average daily trading volume, of 9,600 shares, the days-to-cover ratio is currently 1.2 days. Currently, 1.2% of the shares of the stock are short sold.
View Addex Therapeutics' Short Interest
.

When is Addex Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our ADXN earnings forecast
.

How were Addex Therapeutics' earnings last quarter?

Addex Therapeutics Ltd (NASDAQ:ADXN) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($14.40) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($14.40). The company had revenue of $0.83 million for the quarter, compared to analysts' expectations of $0.42 million. Addex Therapeutics had a negative trailing twelve-month return on equity of 236.83% and a negative net margin of 550.78%. During the same period in the previous year, the company posted ($15.60) earnings per share.

When did Addex Therapeutics' stock split?

Addex Therapeutics shares reverse split on Monday, October 23rd 2023. The 1-20 reverse split was announced on Monday, October 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Addex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Addex Therapeutics investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY).

Who are Addex Therapeutics' major shareholders?

Addex Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include J. Stern & Co. LLP (10.89%) and Armistice Capital LLC (4.34%).

How do I buy shares of Addex Therapeutics?

Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADXN) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners